Kornimate/medical-research-clean huggingface dataset:
erector spinae block for thoracic surgery

Conditions: Pulmonary Neoplasm; Pulmonary Cancer; Thoracic Diseases; Thoracic Cancer; Thoracic Neoplasms

Summary: the aim of this study is to determine if erector spinae injections with bolus infusions with local anesthetic decrease postsurgical pain and opioid consumption in patients undergoing pulmonary resection surgery.

the research hypothesis for the esb thoracic study is that erector spinae blocks with boluses of bupivacaine infusions will decrease patients' postsurgical pain, and thereby decrease the amount of narcotic pain medication used. this will be of particular use in patients who have an anticoagulation need and are not able to receive more invasive nerve blocks.to achieve appropriate exposure for pulmonary resection surgery, whether open or video-assisted, patients have surgical incision in the lateral thoracic region, including disruption to the tributaries of the spinal nerves. due to this dissection, patients frequently experience significant pain post-operatively. erector spinae blocks with bupivacaine or ropivacaine with bolus infusion therapy have been shown to treat this spinal nerve pain effectively in rib fractures, thoracoscopic surgeries, and breast surgeries. however, there have been no definitive studies evaluating the effectiveness of erector spinae blocks in postoperative pulmonary resection surgery patients. it is expected that patients with erector spinae blocks (esb) will have lower pain visual analogue scores (vas) and lower total opioid consumption. learning more about the effectiveness of esb can help in providing adjunct therapy and thereby minimize post-operative opioids, use of which can add further complications in this group of patients through decreased ventilation and increased atelectasis and hypercarbia. as well, current neuraxial local anesthetic therapy involving epidurals and paravertebral blocks require an absence of anticoagulation in the patient; as a fascial plane block, erector spinae blocks can be safely placed in patients on anticoagulation.

Eligibility criteria:
inclusion criteria: * pulmonary resection * 18\<age\<90 exclusion criteria: * pleurodesis * decortication * emergent surgery * local anesthetic allergy * intraoperative complication (inadvertent hemorrhage or conversion to open surgery) * bilateral pulmonary resection
suicide prevention in prepubertal children

Conditions: Suicidal Ideation; Suicide, Attempted

Summary: suicidal ideation and behaviors are estimated to be as high as 4-16% and 1.5% (respectively) in the general 6-12-year-old population. however, there are currently no validated suicide prevention interventions specifically developed for this population. this study aims to: (1) test the feasibility and acceptability of the safety planning intervention for prepubertal children (c-spi) in 30 children (ages 6-12) who have made a suicide threat, suicidal behavior or reported suicidal ideation, and their parents, and (2) improve the investigator's understanding of suicidal ideation and behaviors in this age group. the results from the current project will be used to further develop the c-spi, and to develop preliminary guidance and associated policy for clinicians to use.

the safety planning intervention (spi) is a brief, protocol-driven and individually tailored tool that uses evidence-based practices for suicide prevention. the spi aims to provide the individual with quick distraction and coping tools to overcome a suicidal crisis without acting upon the suicidal thoughts. the spi was used in the treatment for adolescents suicide attempters study in youth 12-19 and has been found to be feasible and acceptable among adult patients and staff as well as among clinicians who work with adolescents. its effectiveness in reducing suicide risk among veterans has also been confirmed. the spi could be a good fit for children, as it uses concrete ways for the person to recognize their reaction, as well as concrete methods to cope with distress, which fits with the developmental stage of prepubertal children. moreover, the collaborative way in which the personal safety plan is tailored to the suicidal person will allow the engagement of the child in the intervention. the spi is an intervention that is relatively easy to administer and, therefore, if found to be appropriate for this age group, it could be implemented in different child-focused settings, including schools. the aim of the study is to evaluate the acceptability and feasibility of the safety planning intervention for prepubertal children's (c-spi) among suicidal children and their parents. additionally, children will be interviewed and be assessed for impulsivity, attention bias, irritability and coping skills.

Eligibility criteria:
inclusion criteria: * suicidal thoughts or threats in the last six month or suicidal behavior in lifetime * the child and his parent/guardian are english speakers * having a parent /guardian consent to the child participating in this study * the clinician confirmed that the parents are suitable to take part in the intervention exclusion criteria: * diagnosis of a psychotic disorder * intellectual disability
virtual reality versustask-oriented for gait in cp

Conditions: Cerebral Palsy

Summary: the children with hemiplegic cerebral palsy had a longer gait cycle, slower walking speed, and longer support phase than did the healthy children. the support phase was longer than the swing phase in the children with hemiplegic cerebral palsy

this research aims to evaluate the effect of virtual reality (vr) games on balance recovery of children with cerebral palsy (cp) by quantitatively synthesizing the existing literature, and to further determine the impact of vr game intervention (the duration of each intervention, intervention frequency, intervention cycle, and total intervention time) on the balance recovery of children with cp. a high-intensity task-oriented training programme designed to improve hemiplegic gait and physical fitness was feasible in the present study and the effectiveness exceeds a low intensity physiotherapy-programme in terms of gait speed and walking capacity in hemiplegic cp. in a future study, seems appropriate to additionally use measures to evaluate physical fitness and energy expenditure while walking.

Eligibility criteria:
inclusion criteria: 1. their age will ranging from 7 to 9 years. 2. children participated in this study will from both sexes. 3. their degree of spasticity will ranged from mild to moderate according to modified ashworth scale. 4. all children will able to walk supported or unsupported by the therapist. 5. children will able to follow the instructions during testing and training. 6. all children had no fixed contractures or deformities at the lower limb. exclusion criteria: 1. children with visual or auditory problems. 2. children with history of epilepsy. 3. children with structural joints deformities of the lower limbs. 4. children with history of surgical interference in lower limbs less than one year. 5. children with convulsions and fixed contractures. 6. uncooperative children.

Keywords: wii sport task oriented training hemiplegic cerebral palsy
autologous bone marrow mesenchymal stem cells in the treatment of patients with amyotrophic lateral sclerosis

Conditions: Amyotrophic Lateral Sclerosis

Summary: the goal of this study is to investigate the safety and tolerability of autologous bone marrow-derived mesenchymal stem cells administration in the individuals with diagnosed amyotrophic lateral sclerosis.

amyotrophic lateral sclerosis (als) is one of the progressive neurodegenerative disorders, affecting upper and lower motor neurons in the cerebral cortex, brainstem and spinal cord. hence, the signs of damage motor neurons are both at the peripheral (eg. atrophy), and central (eg. spasticity) level. there is no effective treatment for als and the majority of patients die within 5 years after diagnosis, usually due to respiratory failure. numerous studies on murine models revealed that mesenchymal stem cells (mscs) successfully improve the clinical and pathological features of als. the goal of this nonrandomized, open label study is to investigate the safety and tolerability of autologous bone marrow-derived mesenchymal stem cell transplantation into the individuals with diagnosed amyotrophic lateral sclerosis. this clinical trial is conducted to test the therapeutic (neuroprotective and paracrine) effect of autologous bone marrow-derived mesenchymal stem cells (bm-mscs). all patients enrolled will have a documented history of als disease prior to study enrollment. patients are recruited for a clinical trial not longer than 1 year from disease diagnosis. then, patients are divided into two groups: group i - patients receiving intrathecally one application of bm-mscs and group ii - patients receiving intrathecally three applications (each administration every two months) of bm-mscs. subsequently, autologous bone marrow-derived mesenchymal stem cell transplantation to the cerebrospinal fluid at the site of the spinal cord will be performed. finally, treatment safety, adverse events and exploratory parameters, including electromyographic (emg) studies, forced vital capacity (fvc) and functional rating scale (frs) to establish als progression rate will be recorded throughout the duration and in the post-treatment follow up period.

Eligibility criteria:
inclusion criteria: * diagnosis of the als disease before the cell transplantation (diagnose established following the el escorial criteria for definite als) * good understanding of the protocol and willingness to consent * signed informed consent * disease duration: up to 2 years * fvc \> 50% / pulmonologist certificate about respiratory function of the patient exclusion criteria: * cancer, * autoimmune diseases * renal failure, * subject is a respiratory dependent. * subject unwilling or unable to comply with the requirements of the protocol * pregnancy, breastfeeding
application of al18f-octreotide pet/ct in neuroendocrine tumor

Conditions: Neuroendocrine Tumor

Summary: this is an open-label whole-body pet/ct study for investigating the value of al18f-octreotide pet/ct in patients with neuroendocrine tumor

octreotide is an artificial replacement for the natural growth hormone inhibitor in humans. it is a small peptide hormone consisting of 14 amino acids and is widely distributed in neuroendocrine cells, with the highest density in the brain, peripheral neurons, endocrine pancreas and gastrointestinal tract. under pathological conditions, some tumour cells show overexpression of growth inhibitory receptors, such as endocrine tumours of the pancreas, pituitary adenomas, pheochromocytomas, paragangliomas, carcinoid tumours, medullary thyroid carcinomas, small cell lung carcinomas and other neuroendocrine tumours. therefore, the sensitivity and specificity of octreotide imaging is high. this study will provide a visual, reproducible and non-invasive imaging method for the diagnosis of neuroendocrine tumours through al18f-octreotide pct/ct imaging, providing an intuitive and clear imaging basis for clinical diagnosis, differential diagnosis and treatment, contributing to the development of medicine and science in the field of positron imaging.

Eligibility criteria:
inclusion criteria: * patients with suspected or clearly diagnosed neuroendocrine tumor * signed written consent. * willing and able to cooperate with all projects in this study. exclusion criteria: * pregnancy; * breastfeeding; * any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
efficacy and safety of 177lu-edotreotide prrt in gep-net patients

Conditions: Neuroendocrine Tumors

Summary: the purpose of the study is to evaluate efficacy and safety of peptide receptor radionuclide therapy (prrt) with 177lu-edotreotide compared to targeted molecular therapy with everolimus in patients with inoperable, progressive, somatostatin receptor-positive (sstr+), neuroendocrine tumours of gastroenteric or pancreatic origin (gep-net).


Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of well-differentiated neuro-endocrine tumour of non-functional gastroenteric origin (ge-net) or both functional or non-functional pancreatic origin (p-net) * measurable disease per recist 1.1 * somatostatin receptor positive (sstr+) disease * progressive disease based on recist 1.1. criteria as evidenced by two morphological imaging examinations made with the same imaging method (either ct or mri) exclusion criteria: * known hypersensitivity to edotreotide or everolimus * known hypersensitivity to dota, lutetium-177, or any excipient of edotreotide or everolimus or any other rapamycin derivative * prior exposure to any peptide receptor radionuclide therapy (prrt) * prior therapy with mtor inhibitors * prior efr (external field radiation) to gep-net lesions within 90 days before randomisation or radioembolisation therapy * therapy with an investigational compound and/or medical device within 30 days prior to randomisation * indication for surgical lesion removal with curative potential * planned alternative therapy (for the period of study participation) * serious non-malignant disease * clinically relevant renal, hepatic, cardiovascular, or haematological organ dysfunction, potentially interfering with the safety of the study treatments * pregnant or breast-feeding women * subjects not able to declare meaningful informed consent on their own (e.g. with legal guardian for mental disorders) or any other vulnerable population to that sense (e.g. persons institutionalised, incarcerated etc.).

Keywords: non-functional and functional p-net non-functional ge-net
the effect of dexmedetomidine for suprascapular nerve block with axillary nerve block

Conditions: Suprascapular Nerve Block; Axillary Nerve Block; Dexmedetomidine; Arthroscopic Rotator Cuff Repair; Postoperative Pain; Pain Related Cytokine

Summary: suprascapular nerve block (ssnb) is most commonly used for relieving postoperative pain of arthroscopic rotator cuff repair and it can be used in combination with axillary nerve block (anb). dexmedetomidine (dex) is known as a type of alpha agonist which can elongate the duration of regional block. the aim of this study was to compare the results of dexmedetomidine combined with ssnb and anb with ssnb and anb alone on postoperative pain, satisfaction, and pain-related cytokines within the first 48 hours after arthroscopic rotator cuff repair. forty patients with rotator cuff tears who had undergone arthroscopic rotator cuff repair were enrolled in this single center, double-blinded randomized controlled trial study. twenty patients were randomly allocated to group 1 and received ultrasound-guided ssnb and anb using each mixture of 0.5 ml (50 μg) of dex and 9.5 ml of 0.75% ropivacaine preemptively. the other 20 patients were allocated to group 2 and underwent ultrasound-guided ssnb and anb alone using a mixture of 0.5 ml of normal saline and 9.5 ml of ropivacaine. the visual analog scale (vas) for pain and patient satisfaction (sat) scores were checked within 48 h postoperatively. the plasma interleukin (il)-6, -8,-1β, cortisol, and serotonin levels were also measured within 48 h postoperatively.


Eligibility criteria:
inclusion criteria: * defined rotator cuff tear on preoperative mri, which indicated repair * acceptable arthroscopic surgery, including rotator cuff repair * patients \>20 years old * acceptable routine regional blocks and patient-controlled analgesia (pca) exclusion criteria: * did not undergo arthroscopic rotator cuff repair * stopped pca before 48 h postoperatively due to side effects * had a concomitant operation for a bankart lesion * had a history of shoulder operation or fracture * had a concomitant neurological disorder around the shoulder * underwent conversion to open surgery from the arthroscopy * had contraindications for the routine regional blocks used in this study * had an known allergy or hypersensitivity against ropivacaine or dexmedetomidine, including other amino-amide local anesthetics or α2-adrenoceptor agonists.
feasibility study evaluating the efficacy of a wireless vital signs monitor for critically ill newborns in kenya

Conditions: Newborn Morbidity; Newborn Complication

Summary: the neoguard device is a 4-in-1 wearable vital signs monitor designed to continuously measure temperature, pulse rate (pr), respiratory rate (rr) and blood oxygen saturation (spo2) in newborns. in this study, researchers will evaluate the feasibility of the neoguard device at two rural health facilities in western kenya and assess the preliminary efficacy of the technology in improving health outcomes for newborns. this is a pre/post intervention study. the standard-of-care arm (n=223) will be enrolled between 20 oct - 20 nov, 2020 and the neoguard intervention arm (n=223) will be enrolled between 1 - 31 dec, 2020.


Eligibility criteria:
inclusion criteria: * age \<28 days * admitted to the neonatal intensive care unit * weight at birth/admission ≥2000 g * low-to-moderate disease severity as determined by the signs of inflammation in children that kill (sick) score card (sick score ≤2.4 at admission is eligible) * parent/guardian willing to provide informed consent for their newborn to participate in study exclusion criteria: * age \>28 days * has a condition that impairs them from wearing the device, such as hydrocephaly. * weight at birth \<2000 g * very severe disease status (sick score \>2.4 at admission)

Keywords: newborn health newborn morbidity newborn critical care
direct peritoneal resuscitation for intra-abdominal catastrophes

Conditions: Intestinal Perforation; Intestinal Obstruction; Trauma Abdomen

Summary: it is a retrospective study. patients, who presented with either traumatic or general surgery emergencies, undergone exploratory laparotomy, had an open abdomen management and received direct peritoneal resuscitation in addition to standard resuscitation will be considered as meeting the criteria to collect the data.

due to the high volume of patient transfers from different facilities with difficult intra-abdominal pathologies and the high case-mix index at westchester medical center, we see many patients who require re-operations and open abdominal management. since july1st of 2020 we have been using dpr in addition to standard iv fluids on all patients who undergo open abdominal management and it is now standard of care at our facility. we plan to collect the data from all qualified subjects who received drp since 7/1/2020 to 6/30/2022.

Eligibility criteria:
inclusion criteria: * adult patients 18 years of age or older. * trauma or general surgery patients who undergo emergency abdominal surgery via laparotomy and who had open abdominal management during the index procedure at our institution. * patients who are transferred to our institution with an already open abdomen will also be eligible if they required continued open abdominal management. exclusion criteria: * patients \<18 years are excluded.
fat supplementation on dumping syndrome related symptoms after gastric surgery

Conditions: Dumping Syndrome; Gastric Surgery

Summary: the purpose of the study is the investigation of the effect of fat supplement on gastric emptying rate and the appearance of symptoms of dumping syndrome in patients who have undergone gastrointestinal- duodenal surgery. patients who have undergone bariatric surgery have been examined for the presence of the dumping syndrome, with glucose measurements, the sigstad's questionnaire and questionnaire of arts. patients diagnosed positive, reiterated the examination process in a second meeting consuming an extra fat supplement. the data obtained on the different appointments were compared between the two groups in a cross over design.


Eligibility criteria:
inclusion criteria: * patients with dumping syndrome exclusion criteria: * patients with diabetes mellitus type 1 and 2 * patients with impaired balance of fluids and electrolytes * patients on diuretics pills or corticosteroids or hypoglycemic tablets and insulin.

Keywords: dumping syndrome fat supplement gastric surgery
tympanometric analysis in cleft palate

Conditions: Bilateral Complete Cleft Lip and/or Alveolus

Summary: purpose: characterize the profile of tympanometric patients with cleft lip and palate in the post surgery period and correlate it with the time of palatoplasty. methods: the sample consisted of 16 patients with cleft lip or palate totaling 32 ears treated at a public university hospital in cuiabá (mt)- brazil, in the post surgery moment that varied from three months to 33 years. were sampled patients of both sexes, pediatrics and adults.


Eligibility criteria:
inclusion criteria: * cleft incisive trans unilateral or bilateral * post-foramen complete or incomplete exclusion criteria: * isolated cleft lip * associated syndromes * malformation of ear
targeted next-generation sequencing panel for identification of germline mutations in early onset cancers with sporadic or hereditary presentation

Conditions: Breast Cancer; Ovarian Cancer; Colorectal Cancer; Pediatric Cancers; Multiple Primary Malignant Tumours

Summary: despite relevant clinical and/or familial presentations suggesting a hereditary predisposition (early-onset, multiple primary tumors, familial aggregation), targeted genomic analysis based on the phenotype are often non contributive. as somatic cancer genes are limited, the hypothesis is that the targeted next-generation sequencing of 200 genes, selected for their implications in cancers may contribute to the understanding of many selected patients' presentation by the identification of germline deleterious mutations, and may identified phenotype overlapping and/or mosaicisms. the focus will be put on early-onset breast, ovarian, colorectal cancer or pediatric cancers and multiple primary tumors.


Eligibility criteria:
inclusion criteria : * older than 18 or parental agreement in case of children. for patient with early-onset breast cancer : * invasive breast cancer, regardless of histological type or stage, diagnosed before 31 years. * sporadic or familial presentation * no genomic alterations of brca1, brca2 or tp53 for patient with early-onset ovarian cancer : * invasive ovarian cancer, regardless of histological type or stage, diagnosed before 41 years. * sporadic or familial presentation * no genomic alterations of brca1, brca2 patient with early-onset colorectal cancer : * invasive colorectal cancer diagnosed before 31 years. * sporadic or familial presentation * no genomic alteration of msh2, mlh1 or msh6 in case of hnpcc presentation * no genomic alteration of apc, mutyh, smad4, bmpr1a, pten or stk11 in case of adenomatous polyposis or hamartoma presentation patient with pediatric cancer : * non haematological tumour diagnosed before 16 years, with li-fraumeni presentation. * no genomic alteration of tp53 patient with multiple primary malignant tumours : * multiple synchronous or metachronous primary malignant tumors with early-onset * no syndromic presentation exclusion criteria: * any already known deleterious mutations according to the patient's phenotype